X
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
Details:
The agreement is signed for the continued development and manufacturing of MBP134, an experimental combination monoclonal antibody treatment for Sudan ebolavirus (SUDV).
Lead Product(s): MBP134
Therapeutic Area: Infections and Infectious Diseases Product Name: MBP134
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: KBI Biopharma
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement January 23, 2023
Details:
The pan-Ebola program, MBP134, is a two mAb cocktail that has demonstrated effectiveness against Sudan virus (SUDV), Zaire Ebola virus (EBOV), Bundibugyo virus (BDBV), Taï Forest virus (TAFV), Reston virus (RESTV), and Bombali ebolavirus (BOMV).
Lead Product(s): MBP134
Therapeutic Area: Infections and Infectious Diseases Product Name: MBP134
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Aridis Pharmaceuticals
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Agreement December 05, 2022
Details:
Mapp Biopharmaceutical has contracted Avid to provide process transfer, scale-up and clinical manufacturing services to support one of its development programs for a novel antiviral drug candidate. Avid and Mapp will immediately commence the initial phase of the project.
Lead Product(s): Human monoclonal antiviral antibody
Therapeutic Area: Infections and Infectious Diseases Product Name: Undisclosed
Highest Development Status: IND EnablingProduct Type: Large molecule
Partner/Sponsor/Collaborator: Avid Bioservices
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Partnership August 26, 2020
FULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results] 
Market Place
